JP7846627B2 - 新規な免疫活性インターロイキン2アナログ - Google Patents

新規な免疫活性インターロイキン2アナログ

Info

Publication number
JP7846627B2
JP7846627B2 JP2022559531A JP2022559531A JP7846627B2 JP 7846627 B2 JP7846627 B2 JP 7846627B2 JP 2022559531 A JP2022559531 A JP 2022559531A JP 2022559531 A JP2022559531 A JP 2022559531A JP 7846627 B2 JP7846627 B2 JP 7846627B2
Authority
JP
Japan
Prior art keywords
interleukin
amino acids
amino acid
deleted
analog
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022559531A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023515247A (ja
Inventor
ウ リム オ
サン ユン キム
ヨン ホ ホ
ジン ヨン キム
チョ ロン パク
ジュン ソプ パク
ヒュン ス リュ
Original Assignee
ハンミ ファーマシューティカル カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ハンミ ファーマシューティカル カンパニー リミテッド filed Critical ハンミ ファーマシューティカル カンパニー リミテッド
Publication of JP2023515247A publication Critical patent/JP2023515247A/ja
Priority to JP2023202447A priority Critical patent/JP2024041747A/ja
Application granted granted Critical
Publication of JP7846627B2 publication Critical patent/JP7846627B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP2022559531A 2020-03-31 2021-03-31 新規な免疫活性インターロイキン2アナログ Active JP7846627B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023202447A JP2024041747A (ja) 2020-03-31 2023-11-30 新規な免疫活性インターロイキン2アナログ

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2020-0039476 2020-03-31
KR20200039476 2020-03-31
PCT/KR2021/004028 WO2021201615A1 (ko) 2020-03-31 2021-03-31 신규한 면역 활성 인터루킨 2 아날로그

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023202447A Division JP2024041747A (ja) 2020-03-31 2023-11-30 新規な免疫活性インターロイキン2アナログ

Publications (2)

Publication Number Publication Date
JP2023515247A JP2023515247A (ja) 2023-04-12
JP7846627B2 true JP7846627B2 (ja) 2026-04-15

Family

ID=77930406

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022559531A Active JP7846627B2 (ja) 2020-03-31 2021-03-31 新規な免疫活性インターロイキン2アナログ
JP2023202447A Pending JP2024041747A (ja) 2020-03-31 2023-11-30 新規な免疫活性インターロイキン2アナログ

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023202447A Pending JP2024041747A (ja) 2020-03-31 2023-11-30 新規な免疫活性インターロイキン2アナログ

Country Status (17)

Country Link
US (2) US11746137B2 (cg-RX-API-DMAC7.html)
EP (1) EP4130027A4 (cg-RX-API-DMAC7.html)
JP (2) JP7846627B2 (cg-RX-API-DMAC7.html)
KR (2) KR102545250B1 (cg-RX-API-DMAC7.html)
CN (2) CN115427437B (cg-RX-API-DMAC7.html)
AR (1) AR121713A1 (cg-RX-API-DMAC7.html)
AU (2) AU2021202825B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022018730A2 (cg-RX-API-DMAC7.html)
CA (2) CA3266069A1 (cg-RX-API-DMAC7.html)
CL (2) CL2022002562A1 (cg-RX-API-DMAC7.html)
IL (1) IL295826B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022011893A (cg-RX-API-DMAC7.html)
NZ (1) NZ793819A (cg-RX-API-DMAC7.html)
PE (1) PE20221759A1 (cg-RX-API-DMAC7.html)
TW (1) TWI876021B (cg-RX-API-DMAC7.html)
WO (1) WO2021201615A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202209565B (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR121713A1 (es) * 2020-03-31 2022-06-29 Hanmi Pharm Ind Co Ltd Nuevos análogos de il-2 inmunoestimulantes
TWI815194B (zh) 2020-10-22 2023-09-11 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
KR20240034221A (ko) 2021-07-09 2024-03-13 브라이트 피크 테라퓨틱스 아게 염증성 질환 및 자가면역 질환의 치료를 위한 변형된 il-2 폴리펩티드
KR20230095612A (ko) * 2021-12-22 2023-06-29 한미약품 주식회사 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그
KR102445492B1 (ko) * 2021-12-24 2022-09-21 엔케이젠 주식회사 신규한 펩타이드를 포함하는 자연살해세포 대량증식용 조성물 및 이를 이용한 자연살해세포 대량증식방법
CN114853909A (zh) * 2022-05-13 2022-08-05 南京吉盛澳玛生物医药有限公司 新型IL-2与INFα和Fc融合蛋白的设计、制备及用途
IL317511A (en) 2022-06-16 2025-02-01 Cephalon Llc IL-2 immunoconjugates attenuated by anti-PD-1 antibody and their uses
CN119790064A (zh) * 2022-08-23 2025-04-08 马斯得生物有限公司 Il2变体和包括该il2变体的蛋白复合体
KR20250126198A (ko) 2024-02-15 2025-08-25 한림대학교 산학협력단 인슐린 저항성의 예방 또는 치료를 위한 약학적 조성물

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014502967A (ja) 2010-12-22 2014-02-06 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ インターロイキン2のスーパーアゴニストおよびアンタゴニスト
JP2016533167A (ja) 2013-09-24 2016-10-27 メディシナ セラピューティクス ピーティーイー リミテッド インターロイキン−2融合タンパク質及びその使用
JP2017518361A (ja) 2014-04-24 2017-07-06 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
WO2018234862A1 (en) 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3285989A (en) * 1987-11-25 1989-06-14 Cetus Corporation Treatment of infections caused by a primary immunodeficiency with interleukin-2
AU627477B2 (en) * 1988-07-05 1992-08-27 Amgen, Inc. Interleukin ii analogs
CA2019714A1 (en) 1989-06-27 1990-12-27 Richard A. Chizzonite Process for the determination of interleukins
DZ2788A1 (fr) 1998-05-15 2003-12-01 Bayer Ag Agonistes et antagonistes selectifs à IL-2.
CZ305123B6 (cs) * 1999-10-04 2015-05-13 Novartis Vaccines And Diagnostics, Inc. Způsob výroby kapalného farmaceutického prostředku
WO2004022593A2 (en) 2002-09-09 2004-03-18 Nautilus Biotech Rational evolution of cytokines for higher stability, the cytokines and encoding nucleic acid molecules
WO2005007121A2 (en) 2003-07-18 2005-01-27 Massachusetts Institute Of Technology Mutant interleukin-2(il-2) polypeptides
KR20070003934A (ko) * 2004-03-05 2007-01-05 노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 치료제의 환자 내약성을 예측하기 위한 시험관 내 테스트시스템
CN1930300A (zh) 2004-03-05 2007-03-14 希龙公司 预测患者治疗药物耐受性的体外试验系统
AU2007201663A1 (en) 2007-04-16 2008-10-30 Nautilus Biotech Oral dosage formulations of protease resistant polypeptides
CN102462837B (zh) 2010-11-19 2016-08-03 生物林格斯Ip有限公司 抗炎组合物
KR20140106452A (ko) 2013-02-26 2014-09-03 한미약품 주식회사 신규한 인슐린 아날로그 및 이의 용도
MY186251A (en) 2014-01-20 2021-06-30 Hanmi Pharm Ind Co Ltd Long-acting insulin and use thereof
CN107148279B (zh) 2014-10-21 2021-09-03 赛生药品股份国际有限公司 用免疫刺激剂治疗癌症
CN104403004B (zh) * 2014-11-24 2017-10-13 苏州丁孚靶点生物技术有限公司 抗体‑干扰素异二聚体的制备和用途
KR20160134989A (ko) 2015-05-14 2016-11-24 순천향대학교 산학협력단 인간 인터류킨-2 단백질을 포함하는 약학조성물
CN107266553A (zh) * 2016-04-08 2017-10-20 南京康志制药有限公司 高效人白细胞介素ⅱ突变体融合蛋白及其应用
KR20240115933A (ko) * 2016-05-04 2024-07-26 암젠 인크 T-조절 세포의 증식을 위한 인터류킨-2 뮤테인
CN110913954A (zh) * 2017-03-03 2020-03-24 黑曜石疗法公司 免疫疗法的组合物和方法
JP7356726B2 (ja) * 2017-09-25 2023-10-05 ディンフー バイオターゲット カンパニー リミテッド タンパク性ヘテロ二量体及びその使用
US10946068B2 (en) * 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
JP7534215B2 (ja) * 2018-01-24 2024-08-14 ベイジン パーカンズ オンコロジー カンパニー リミテッド サイトカイン融合タンパク質
CN108503714A (zh) 2018-04-10 2018-09-07 浙江科途医学科技有限公司 一种人白介素2和抗人上皮细胞黏附分子单链抗体融合蛋白及其应用
MX2020012251A (es) * 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
AU2019288496B2 (en) * 2018-06-22 2024-11-21 Cugene Inc. Interleukin-2 variants and methods of uses thereof
US12522640B2 (en) * 2018-07-24 2026-01-13 BioNTech SE IL2 agonists
SG11202005873QA (en) * 2018-09-17 2020-07-29 Gi Innovation Inc Fusion protein comprising il-2 protein and cd80 protein, and use thereof
CA3098930A1 (en) * 2018-09-21 2020-03-26 Innovent Biologics (Suzhou) Co., Ltd. Novel interleukin-2 and use thereof
MX2021005708A (es) * 2018-11-16 2021-09-21 Bristol Myers Squibb Co Anticuerpos anti grupo 2a del receptor inhibidor de células asesinas naturales (anti-nkg2a) y usos de los mismos.
US20220025007A1 (en) * 2018-12-21 2022-01-27 Hanmi Pharm. Co., Ltd. Novel immunosuppressive interleukin 2
CN111944036B (zh) 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
CN114437198A (zh) 2019-12-17 2022-05-06 北京志道生物科技有限公司 白介素-2衍生物
BR112022017656A2 (pt) 2020-03-05 2022-10-18 Univ Leland Stanford Junior Variantes de il-2 concebidas
AR121713A1 (es) * 2020-03-31 2022-06-29 Hanmi Pharm Ind Co Ltd Nuevos análogos de il-2 inmunoestimulantes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014502967A (ja) 2010-12-22 2014-02-06 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ インターロイキン2のスーパーアゴニストおよびアンタゴニスト
JP2016533167A (ja) 2013-09-24 2016-10-27 メディシナ セラピューティクス ピーティーイー リミテッド インターロイキン−2融合タンパク質及びその使用
JP2017518361A (ja) 2014-04-24 2017-07-06 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー インターロイキン−2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト
WO2018234862A1 (en) 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof

Also Published As

Publication number Publication date
NZ793819A (en) 2026-03-27
US11746137B2 (en) 2023-09-05
CA3169564C (en) 2025-05-06
TW202204387A (zh) 2022-02-01
CL2026001105A1 (es) 2026-05-15
KR20230088656A (ko) 2023-06-20
CN118271419A (zh) 2024-07-02
WO2021201615A1 (ko) 2021-10-07
KR102946368B1 (ko) 2026-04-01
EP4130027A1 (en) 2023-02-08
KR102545250B1 (ko) 2023-06-21
US20230348550A1 (en) 2023-11-02
AU2021202825B2 (en) 2022-06-30
PE20221759A1 (es) 2022-11-11
IL295826A (en) 2022-10-01
JP2023515247A (ja) 2023-04-12
ZA202209565B (en) 2023-12-20
IL295826B2 (en) 2025-11-01
CA3169564A1 (en) 2021-10-07
CL2022002562A1 (es) 2023-03-17
EP4130027A4 (en) 2024-08-14
IL295826B1 (en) 2025-07-01
BR112022018730A2 (pt) 2022-11-01
US20230124171A1 (en) 2023-04-20
AU2022203841A1 (en) 2022-06-23
JP2024041747A (ja) 2024-03-27
KR20210122200A (ko) 2021-10-08
AR121713A1 (es) 2022-06-29
CA3266069A1 (en) 2026-03-02
TWI876021B (zh) 2025-03-11
CN115427437A (zh) 2022-12-02
MX2022011893A (es) 2022-10-18
AU2021202825A1 (en) 2021-10-14
CN115427437B (zh) 2024-04-19
US12415842B2 (en) 2025-09-16

Similar Documents

Publication Publication Date Title
KR102946368B1 (ko) 신규한 면역 활성 인터루킨 2 아날로그
US20220025007A1 (en) Novel immunosuppressive interleukin 2
CN112552391B (zh) 一种重组白介素-15类似物
TWI922649B (zh) 免疫刺激il-2類似物的新穎接合物及其製備方法
RU2843530C1 (ru) Новые иммуностимулирующие аналоги интерлейкина-2
HK40079776A (en) Novel immunoactive interleukin 2 analog
KR20230095612A (ko) 신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그
EP4678181A1 (en) Combination therapy of interleukin-2 analog or conjugate thereof and immune checkpoint inhibitor for prevention or treatment of cancer
HK40100172A (en) Novel immunoactive interleukin 2 analog conjugate and method for preparing same
WO2024046280A1 (zh) 一种聚乙二醇修饰的il-21衍生物及其应用
EA049515B1 (ru) Новый конъюгат иммуностимулирующего аналога интерлейкина-2 и способ его получения
JP2026509259A (ja) インターロイキン2アナログ又はその結合体を含む癌予防又は治療用薬学的組成物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220929

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220929

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20220929

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230323

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230620

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230731

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231130

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231206

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260403

R150 Certificate of patent or registration of utility model

Ref document number: 7846627

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150